<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04731155</url>
  </required_header>
  <id_info>
    <org_study_id>2021HL</org_study_id>
    <nct_id>NCT04731155</nct_id>
  </id_info>
  <brief_title>Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction</brief_title>
  <acronym>PERFECT-AMI</acronym>
  <official_title>Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Tong Ren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Tong Ren Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospect, multi-center, random study to investigate whether early offering PCSK9&#xD;
      inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after&#xD;
      primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects&#xD;
      will be enrolled in this study after consent information. After randomization, the control&#xD;
      group will receive standard therapy for AMI including PPCI. The experiment group will receive&#xD;
      first PCSK9 inhibitor before PPCI, then twice a month until 3 months later. Six month after&#xD;
      AMI, Myocardial salvage index will be used to evaluate ventricular remodeling. TnI peaking&#xD;
      time and LDL control rates also will be recorded and compared.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>myocardial salvage index measured by MRI</measure>
    <time_frame>one week after PPCI</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>myocardial salvage index measured by MRI</measure>
    <time_frame>six months after PPCI</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>eject fraction measured by MRI</measure>
    <time_frame>one week after PPCI</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>eject fraction measured by MRI</measure>
    <time_frame>six month after PPCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change of serum level of TnI/T</measure>
    <time_frame>0,6 ,12,18 , 24 ,30,and 36 hours after PPCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL -C control rate</measure>
    <time_frame>the first month after PPCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the serum lever of hsCRP</measure>
    <time_frame>Baseline (before PPCI)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the serum lever of hsCRP</measure>
    <time_frame>one week after PPCI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Early PCSK9 Inhibitor on Ventricular Remodling</condition>
  <arm_group>
    <arm_group_label>standard group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>experiment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCSK9 inhibitor （Alirocumab）plus standard medications</intervention_name>
    <description>PCSK9 inhibitor（Alirocumab） was giving to subjects before PPCI and continued twice a month until 3 month after AMI</description>
    <arm_group_label>experiment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard medications</intervention_name>
    <description>standard medications was giving to subjects according guidelines</description>
    <arm_group_label>standard group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be at least 18 years of age and less than 80 years old&#xD;
&#xD;
          2. Patients should have undergone successful percutaneous coronary intervention with&#xD;
             drug-eluting stent for AMI and LAD should be the only culprit vessel.&#xD;
&#xD;
          3. Subject understand the study requirements and the treatment procedures and provided&#xD;
             informed consent before the procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female of childbearing potential, unless a recent pregnancy test is negative, who&#xD;
             possibly plan to become pregnant any time after enrollment into this study&#xD;
&#xD;
          2. Known hypersensitivity or contraindication to study medications&#xD;
&#xD;
          3. Plan to receive revascularization in next six month.&#xD;
&#xD;
          4. Have received revascularization before.&#xD;
&#xD;
          5. Subjects with life expectation less than one year.&#xD;
&#xD;
          6. Subjects with active malignant tumor&#xD;
&#xD;
          7. subjects with severe liver or renal dysfunction（ALT &gt;5倍ULA，eGFR&lt;15ml/min/1.73mm2）&#xD;
&#xD;
          8. Other conditions which the investigators think not applicable to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lei Hou, Doctor</last_name>
    <phone>13564868096</phone>
    <email>Dr_houlei@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongren Hospital, Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Hou, Doctor</last_name>
      <phone>13564868096</phone>
      <email>Dr_houlei@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai tenth people's hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 23, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Tong Ren Hospital</investigator_affiliation>
    <investigator_full_name>Hou Lei</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

